Generic Injectable Market
According to Intent Market Research, the Generic Injectable Market is expected to grow from USD 91.3 billion in 2024-e at a CAGR of 10.0% to touch USD 178.1 billion by 2030. The Generic Injectable Market is dominated by key players such as Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V. (Now Viatris), Baxter International Inc., Fresenius Kabi AG, Amgen Inc., Cipla Ltd., Dr. Reddy's Laboratories, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Hospira, Inc. (Acquired by Pfizer), Biocon Ltd., Wockhardt Ltd., Hetero Drugs, Aurobindo Pharma.